Large and Diverse Pipeline
The liver cancer pipeline
contains 238 products in active development, approximately 47% of which are
first-in-class. The percentage of the pipeline devoted to innovative products
is considerably larger than both the industry and oncology average, which is a
promising sign for novel therapeutics reaching the liver cancer market.
View
Full Report with TOC @ http://www.radiantinsights.com/research/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation
The contrast between the market
and pipeline is vast. Analysis showed that the market contains 70 products, the
majority of which are generic formulations of chemotherapies that are not
frequently used in treatment, particularly in advanced-stage patients. Nexavar
(sorafenib) is the dominant therapeutic on the market, and is also the only
targeted therapy that is in regular use for advanced-stage liver cancer
patients. However, pipeline analysis revealed that targeted therapies aimed at
the underlying oncogenic signaling pathways are under much greater focus in the
pipeline than in the market. The success of targeted therapies across the
oncology market as a whole implies that the diversity and innovation in the
pipeline is a promising sign, with products currently in development having the
potential to transform and improve the relatively open liver cancer market.
Alignment of First-in-Class
Molecular Targets with Disease Causation
The liver cancer pipeline is
showing signs of adapting to the increasing understanding of aberrant signaling
pathways and causes of liver cancer. A large portion of pipeline products
target components of known dysfunctional signaling pathways, such as Wnt/ß–catenin
signaling, which is commonly mutated in liver cancer tumor samples. By aligning
the treatment with specific disease-causing features, the damaging off-target
cytotoxic effects of treatment can be reduced, resulting in safer and more
efficacious therapies.
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
No comments:
Post a Comment